Background: The variety of beneficial effects of green tea has been reported. Epigallocatechin-3-gallate (EGCG) is a major component of green tea extract. The biological activity of EGCG includes anti-allergic and anti-inflammatory activities. However, the precise effect of EGCG on the allergic airway inflammation has not been fully defined.
Introduction
Overproduction of mucus plays an important pathophysiologic factor in allergic airway inflammations, such as asthma and allergic rhinitis. The excessive mucus at respiratory tracts causes inflammation by bacterial infection. Furthermore, the mucus may become more densely packed and can lead to airway closure (1) . About 2% of mucus is comprised about of mucins.
Mucins are highly glycosylated proteins which are responsible for viscoelastic properties of mucus (2) . Mucins are subdivided into secretory and membrane associated forms (3) . Among the mucins, MUC5AC, MUC5B, and MUC8 are representative secretory mucin genes in the human airway (1) . In the allergic airway inflammation, airway mucins are produced and secreted in increased quantities (4) . Epigallocatechin-3-gallate (EGCG), a major component of green tea extract, has various functions including reduction of cholesterol and antioxidant activity, which prevents cellular injury due C o r r e c t e d p r o o f to oxidative stress (5) (6) (7) . Recently, several studies have reported the anti-inflammatory or anti-allergic effect of EGCG: EGCG can counteract allergic asthma-like reaction in sensitized guinea pigs by modulating nitric oxide synthase activity (8) . EGCG increases inflammatory cell migration by suppressing matrix metalloprotease (MMP)-9 production and reactive oxygen species (ROS) generation in the murine model of asthma (9) . However, the precise mechanism of action about anti-inflammatory and allergic effects of EGCG has not been totally defined. In our previous study on mucin-producing human NCI-H292 airway epithelial cells, the results revealed that EGCG down-regulates phorbol 12-myristate 13-acetate (PMA)-induced MUC5B gene expression: p38 mitogen-activated protein kinase (MAPK) and MMP-9 may be an important mediator of PMA-induced MUC5B expression (10) . In the present study, we aim to determine the effect and the brief signaling pathway of EGCG in the asthma model-mouse and the nasal epithelial cells of patients with allergic rhinitis. seconds. Data were normalized to glyceraldehydes-3-phosphate dehydrogenase (GAPDH). Amplification specificity was evaluated using the melting curve following the manufacturer's instructions (Roche Applied Science). Primer sequences and conditions used were according to previously published studies of MUC5B, MMP-9, and GAPDH (6, 11) .
Materials and methods
Immunoassay for MUC5B protein 
Western blot analysis of p38 MAPK, ERK1/2 MAPK, and MMP-9
Samples of the extracted lung tissues from asthma model-mice were seeded in wells of a 6-well plate and treated with EGCG.
The cells were exposed to trypsin, and formed into pellets at 700 g at 4 o C and pellets were resuspended in lysis buffer. The preparation was then clarified by centrifugation, and the supernatant was saved as a whole-cell lysate. Proteins (20 µg) were separated using 10% reducing Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroblotted onto a nitrocellulose membrane. The membrane was blocked with 5% nonfat dry milk, followed by incubation with the indicated primary antibody against p38, ERK1/2, or human monoclonal MMP-9 antibody for 4 hours. Subsequently, the membrane was incubated for 1 hour with the proper secondary antibody conjugated to HRP, and developed using an enhanced chemiluminescence kit (Perkin Elmer Life Sciences). Bands were detected after exposure to xray film for 10 seconds. mRNA expression of the asthma group was significantly higher than the control group, and MUC5B mRNA expression of the asthma + EGCG group was significantly lower than asthma group; (A). ELISA showed that MUC5B protein production of the asthma group was significantly higher than the control group, and MUC5B protein production of the asthma + EGCG group was significantly lower than the asthma group; (B). Bars represent the averages ± S.D. of three independent experiments in triplicate. *p < 0.05 compared with the control, †p < 0.05 compared with the asthma. Con, control.
Statistical analysis
Statistical analysis was performed using SPSS, version 12.0 (SPSS, Chicago, IL, USA). Data comparison was done with
Kruskal-Wallis ANOVA test, followed by the Mann-Whitney test as a post hoc analysis. For all tests, a p-value < 0.05 was considered statistically significant.
Results

EGCG decreases mucus production and MUC5B expression in the asthma model-mouse
To investigate the effect of EGCG on MUC5B expression in the asthma model-mouse, MUC5B mRNA expression and protein production were analyzed by real-time PCR and ELISA. MUC5B mRNA expression and protein production of the asthma group were significantly higher than the control group. MUC5B mRNA expression and protein production of the asthma + EGCG group
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were significantly lower than the asthma group ( Figures 1A and   B ).
EGCG decreases mucus production in histological study of the asthma model-mouse
To confirm the effect of EGCG on mucus production and MUC5B
expression in the asthma model-mouse, a histologic study and immunohistochemical analysis were performed. Increased amount of mucus production was observed in the bronchioles of the asthma group ( Figure 2B ), compared to the control group (Figure 2A) , and decreased mucus production in the asthma + EGCG group ( Figure 2C ) than in the asthma group. In addition, increased immunoreactivity for MUC5B was observed in the bronchioles of the asthma group ( Figure 2E ), compared to the control group ( Figure 2D ), and decreased immunoreactivity for MUC5B in the asthma + EGCG group ( Figure 2F ) than in the asthma group.
EGCG inhibits p38 MAPK and MMP-9 expression in the asthma model-mouse
To investigate the brief signaling pathway associated with EGCG in the asthma model-mouse, ERK1/2 and p38 MAPK expression were analyzed by Western blot. p38 MAPK expression of the asthma group was significantly higher than the control group, and p38 MAPK expression of the asthma + EGCG group was significantly lower than the asthma group. However, ERK1/2 MAPK expression did not change ( Figure 3A) . To investigate the effect of EGCG on MMP-9 expression in asthma model-mice, MMP-9 expression was analyzed by real-time PCR and Western blot. MMP-9 expression was significantly higher in the asthma group than the control group, and MMP-9 expression of the asthma + EGCG group was significantly lower than the asthma group ( Figures 3B and C) .
EGCG inhibits MMP-9 and MUC5B expression in the nasal epithelial cells of patients with allergic rhinitis
To evaluate the effect of EGCG on MMP-9 and MUC5B expression in the nasal epithelial cells of patients with allergic rhinitis under inflammatory condition, primary cultured cells was stimulated by PMA, MUC5B and MMP-9 mRNA expression was analyzed by real-time PCR. The result showed that PMA-induces MMP-9 and MUC5B over-expression and this was significantly attenuated by EGCG ( Figures 4A and B) .
Discussion
Allergic airway inflammations, such as asthma and allergic rhinitis, are characterized by airway hyper-responsiveness and mucus overproduction. The properties of mucus depend on its C o r r e c t e d p r o o f Figure 3 . Effect of EGCG on p38 MAPK expression and MMP-9 expression in the asthma model-mouse. Western blot showed that p38 MAPK expression of the asthma group was significantly higher than the control group, and p38 MAPK expression of the asthma + EGCG group was significantly lower than the asthma group. But, ERK1/2 MAPK expression did not change; (A). Real-time PCR showed that MMP-9 mRNA expression of the asthma group was significantly higher than the control group, and MMP-9 mRNA expression of the asthma + EGCG group was significantly lower than the asthma group; (B). Western blot showed that MMP-9 expression of the asthma group was significantly higher than the control group, and MMP-9 expression of the asthma + EGCG group was significantly lower than the asthma group; (C). Bars represent the averages ± S.D. of three independent experiments in triplicate. *P < 0.05 compared with the control, †P < 0.05 compared with the asthma. Con, control. content with mucins, which are regulated by a variety of inflammatory mediators. PMA, a protein kinase C (PKC) activator, has been known as an inflammatory mediator to modulate various cellular events. PMA also plays a significant role in the induction of mucin production in NCI-H292 cells through p38 dependent MMP-9 signaling pathway (10, 12, 13 ). PMA-induced MUC5B expression is regulated through epidermal growth factor receptor (EGFR) and p38-mediated transcriptional mechanism (13) (14) (15) (16) . Therefore, to evaluate the effect of EGCG on allergic rhinitis under inflammatory condition, PMA was used as an inflammatory stimulator for influencing primary cultured human nasal epithelial cells of patients with allergic rhinitis.
MMP-9 is a kind of collagenase that cleaves type IV collagen, which makes up a substantial portion of the basement membrane of airways. MMP-9 plays a role in tissue remodeling in diseases such as asthma and bronchiectasis; increased MMP-9 activity in bronchoalveolar lavage fluid was observed in asthmatic patients compared to healthy subjects (17) . Several studies have demonstrated that MMP-9 mediates mucin gene expression in airway epithelial cells. Acrolein-activated MMP-9, leading to MU-C5AC accumulation, contributes to persistent mucin production in chronic obstructive pulmonary disease (18) . Lipopolysacchari-
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de-induced MUC5AC production may be partially mediated by MMP-9 activation (19) . The results of our previous study revealed that p38 MAPK plays a role in the signaling pathway of PMA-induced MUC5B expression, and EGCG can down-regulate MUC5B
and MMP-9 expression in human NCI-H292 cells. Moreover, MMP-9 may be an important mediator of PMA-induced MUC5B expression, and p38 MAPK plays a role in PMA-induced MMP-9 expression in human NCI-H292 airway epithelial cells (10) .
EGCG, derived from green tea, is the most abundant bioactive polyphenolic substance. Based on a previous safety and pharmacokinetic study, oral administration of EGCG at a daily dose of 800 mg is safe and well tolerated in healthy human subjects. It is likely that a daily 800 mg bolus of EGCG in humans will approximately achieve levels similar to those in sera of EGCG (10 mg/kg/ day) intraperitoneally injected mice (20) . Therefore, many animal studies related to EGCG, including our own, were performed in the concentration range of 3-20 mg/kg/day, which is likely to be achieved under physiologic condition and is not expected to cause any negative side effects (8, 9, 21, 22) . Previous in vitro studies of EGCG on airway epithelial cell, the concentration range of 10-1000 µM was used, because topical application of EGCG on nasal mucosa might achieve the effective experimental dosage of EGCG, allowing the use of EGCG as a therapeutic agent (6, 10, 23) .
Thus, our study using the allergic nasal epithelial cell was performed with EGCG concentrations of 50 and 100 µM.
From the perspective of the protective effect of EGCG on asthma or asthma-like reaction, EGCG can sustain endothelial nitric oxide synthase (NOS) activity and maintain endogenous nitric oxide (NO) generation at physiological levels in an OVAsensitized asthma model. This can counteract the activation of inducible NOS, which releases excess NO and subsequently activates cyclooxygenase-2 to produce inflammatory prostaglandins (8) . In a toluene diisocyanate-sensitized asthma model, EGCG reduced the pathologic lung damage due to the suppression of ROS (9) . In an OVA-sensitized asthma model, EGCG reduced inflammatory cell recruitment and overall inflammatory response in airways and lung tissues (22) . But there has not been any study on the influence of EGCG on mucin gene expression and mucin production in allergic airway inflammations. Therefore, the present study was performed to assess the effect of EGCG on mucin expression in the allergic airway inflammations.
The results showed that increased amount of mucus production in asthma group than the control group, and mucus production was decreased in the asthma + EGCG group. MUC5B, MMP-9, and p38 MAPK expressions were increased in the asthma group and significantly decreased in the asthma + EGCG group. These results suggest that EGCG down-regulates MUC5B expression in the asthma model-mouse. To evaluate the effect of EGCG on allergic rhinitis under inflammatory condition, primary cultured human nasal epithelial cells of patients with allergic rhinitis were stimulated by PMA to make an intensive inflammatory condition. The results also demonstrate that EGCG attenuates MUC5B and MMP-9 expression. We did not investigate the effect of EGCG on human bronchial epithelial cells of patients with asthma in this study. However, we expect the results of such studies to be similar to the results in the current study. Further studies of the effect of EGCG on allergic airway epithelial cells should be performed.
In conclusion, the results of in vivo and in vitro studies suggest that EGCG down-regulates MUC5B expression through the p38 MAPK dependent MMP-9 signaling pathway in allergic airway inflammations. Although overall signaling pathways for regulation of the mucin genes by EGCG in allergic airway inflammations require further confirmation, EGCG could be a novel therapeutic agent for controlling mucin production in allergic airway inflammations.
